Merck & Co. Inc., of Kenilworth, N.J., disclosed data from C-SURFER, the company's phase II/III trial testing a once-daily treatment regimen of grazoprevir (100 mg) and elbasvir (50 mg) in patients with advanced chronic kidney disease (CKD) infected with chronic hepatitis C virus (HCV) genotype 1.